IOLCP2024-10-012024-12-31 IOLCP2024-10-012024-12-31 IOLCP2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member IOLCP2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member IOLCP2024-12-31 IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue03Member IOLCP2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member IOLCP2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member IOLCP2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue03Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults03Member IOLCP2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member IOLCP2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member IOLCP2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults03Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets03Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member IOLCP2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member IOLCP2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member IOLCP2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member IOLCP2024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member IOLCP2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IOLCP2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IOLCP2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IOLCP2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524164 IOLCP NOTLISTED IOL Chemicals and Pharmaceuticals Limited Equity 2024-04-01 2025-03-31 2025-02-12 2025-02-04 INR Crores Third quarter 16:15:00 17:40:00 2025-02-12 2025-02-12 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 5233000000.00 40700000.00 5273700000.00 3359600000.00 0.00 180900000.00 524300000.00 44600000.00 186800000.00 699500000.00 4995700000.00 278000000.00 0.00 278000000.00 43400000.00 29300000.00 72700000.00 0.00 205300000.00 0.00 0.00 0.00 0.00 205300000.00 -1100000.00 204200000.00 0.00 0.00 587100000.00 10 3.50 3.50 0.00 0.00 3.50 3.50 NOTES: 1. The above standalone and consolidated un-audited financial results for the quarter and nine months ended 31st December 2024 have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their meetings held on 12th February 2025. These results have been subjected to limited review by Statutory Auditors who have expressed an unmodified opinion on these results. 2. These financial results are prepared in accordance with the Indian Accounting Standards (“Ind-AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and are in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements} Regulations, 2015. 3. As per Ind-AS 108 - Operating Segments, the Company has two reportable Operating Segments namely Pharmaceuticals and Chemicals. The financial information for these segments has been provided in Financial Results as per Ind-AS 108 - Operating Segments. 4. The Board of Directors has declared an Interim Dividend of Rs 4/- (40%) per Equity Share having face value of Rs 10/- each, for the financial year 2024- 25. The Record Date for the purpose of ascertaining the entitlement of receiving the interim dividend has been fixed on 18th February 2025. 5. The Board of Directors, in their meeting held on 27th December 2024, approved the sub-division / split of each equity share of face value of Rs. 10/- into five Equity Shares of Face Value of Rs. 2/- each, fully paid-up, which was subsequently approved by the shareholders through a Postal Ballot on 31st January 2025. The sub-division / split of shares is in process and will be implemented based on the Record Dated fixed for 11th March 2025. 6. The previous financial period figures have been regrouped/rearranged/restated, wherever considered necessary. by order of the Board IOL Chemicals and Pharmaceuticals Limited sd/- Vikas Gupta Joint Managing Director DIN: 07198109 Date: 12th February 2025 Place: Ludhiana Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 15514300000.00 178800000.00 15693100000.00 10107300000.00 0.00 353300000.00 1641800000.00 107300000.00 534400000.00 2016400000.00 14760500000.00 932600000.00 0.00 932600000.00 176800000.00 59300000.00 236100000.00 0.00 696500000.00 0.00 0.00 0.00 0.00 696500000.00 -14600000.00 681900000.00 0.00 0.00 587100000.00 10 11.87 11.87 0.00 0.00 11.87 11.87 Other Expenses 699500000.00 Other Expenses 2016400000.00 Chemical 2751400000.00 Pharmaceutical 3005800000.00 Unallocated 40700000.00 Chemical 8181500000.00 Pharmaceutical 8900500000.00 Unallocated 178800000.00 5797900000.00 17260800000.00 524200000.00 1567700000.00 5273700000.00 15693100000.00 Chemical 47200000.00 Pharmaceutical 261400000.00 Unallocated 0.00 Chemical 88700000.00 Pharmaceutical 853500000.00 Unallocated 0.00 308600000.00 942200000.00 44600000.00 107300000.00 -14000000.00 -97700000.00 278000000.00 932600000.00 Chemical 5313300000.00 Pharmaceutical 13170300000.00 Unallocated 4575900000.00 23059500000.00 Chemical 2194400000.00 Pharmaceutical 1807200000.00 Unallocated 2260900000.00 6262500000.00 Remeasurement gain/(loss) of defined benefit obligation -600000.00 Remeasurement gain/(loss) of defined benefit obligation -19100000.00 -600000.00 -19100000.00 -100000.00 -4800000.00 Net movement in effective portion of cash flow hedge reserve -900000.00 Net movement in effective portion of cash flow hedge reserve -400000.00 -900000.00 -400000.00 -300000.00 -100000.00